AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10063942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 7569093 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopentol 300 mg/ml
Number of subjects: 60
Study 7569093 — intervention group
Group type: COMPARATOR
Intervention: Iohexol 300 mg/ml
Number of subjects: 60
Study 2208249 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 0
Study 2208249 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 352097 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (P)
Number of subjects: 29
Study 352097 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (P) + Azathioprine (A)
Number of subjects: 29
Study 352097 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (P) + Azathioprine (A) + Cyclophosphamide (C)
Number of subjects: 29
Study 352097 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 29
Study 352097 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 29
Study 31343263 — intervention group
Group type: EXPERIMENTAL
Intervention: RNA extracted from PAXgene Blood RNA tubes stored for 1 month
Number of subjects: 300
Study 31343263 — intervention group
Group type: EXPERIMENTAL
Intervention: RNA extracted from PAXgene Blood RNA tubes stored for 1 year
Number of subjects: 300
Study 31343263 — intervention group
Group type: EXPERIMENTAL
Intervention: RNA extracted from PAXgene Blood RNA tubes stored for 2 years
Number of subjects: 300
Study 31343263 — intervention group
Group type: EXPERIMENTAL
Intervention: RNA extracted from PAXgene Blood RNA tubes stored for 3 years
Number of subjects: 300
Study 31343263 — intervention group
Group type: EXPERIMENTAL
Intervention: RNA extracted from PAXgene Blood RNA tubes stored for 6 years
Number of subjects: 300
Study 28505367 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Information Exchange (HIE) access during medication reconciliation
Number of subjects: 381
Study 28505367 — intervention group
Group type: COMPARATOR
Intervention: Usual care (without HIE access)
Number of subjects: 381
Study 26271132 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Neiguan (PC 6), applied once every two days, 3 days a week for 4 weeks.
Number of subjects: 30
Study 26271132 — intervention group
Group type: COMPARATOR
Intervention: Medication group (basic medication without acupuncture intervention).
Number of subjects: 30
Study 23561865 — intervention group
Group type: EXPERIMENTAL
Intervention: Centering Principle of Pilates Method (performed by LBPG)
Number of subjects: 18
Study 23561865 — intervention group
Group type: COMPARATOR
Intervention: Centering Principle of Pilates Method (performed by CG)
Number of subjects: 18
Study 21749209 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-colony stimulating factor and autologous bone marrow-derived stem/progenitor cells
Number of subjects: 0
Study 21749209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20467641 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g amoxicillin
Number of subjects: 158
Study 20467641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 16826094 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic-on-ceramic (Ce/Ce) implant
Number of subjects: 61
Study 16826094 — intervention group
Group type: COMPARATOR
Intervention: Metal-on-polyethylene (PE) implant
Number of subjects: 61
Study 14616428 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem co-treatment (30 mg or 60 mg twice daily depending on weight)
Number of subjects: 110
Study 14616428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 11097144 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice pretreatment with oral scopolamine 0.5 mg
Number of subjects: 14
Study 11097144 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous scopolamine 0.5 mg
Number of subjects: 14
Study 11097144 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine administration (all routes)
Number of subjects: 14
Study 11097144 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine administration
Number of subjects: 14
Study 9505992 — intervention group
Group type: EXPERIMENTAL
Intervention: Microemulsion oral solution
Number of subjects: 20
Study 9505992 — intervention group
Group type: EXPERIMENTAL
Intervention: Microemulsion soft gelatin capsule
Number of subjects: 20
Study 9505992 — intervention group
Group type: COMPARATOR
Intervention: Conventional oral solution
Number of subjects: 20
Study 9505992 — intervention group
Group type: EXPERIMENTAL
Intervention: Microemulsion capsule (200, 400, 600 mg)
Number of subjects: 20
Study 9505992 — intervention group
Group type: EXPERIMENTAL
Intervention: Microemulsion capsule (400 mg after a fat-rich meal)
Number of subjects: 20
Study 9505992 — intervention group
Group type: EXPERIMENTAL
Intervention: All dose levels of microemulsion formulation
Number of subjects: 20
Study 7504141 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepridil hydrochloride
Number of subjects: 23
Study 3548587 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibratory stimulation at 10, 100, and 200 Hz
Number of subjects: 96
Study 3548587 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 96
Study 3548587 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger probe
Number of subjects: 96
Study 3548587 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller probe
Number of subjects: 96
Study 30824635 — intervention group
Group type: EXPERIMENTAL
Intervention: IV golimumab (GOL) 2 mg/kg
Number of subjects: 208
Study 30824635 — intervention group
Group type: COMPARATOR
Intervention: Placebo (crossover to GOL at weeks 16, 20, and every 8 weeks thereafter)
Number of subjects: 208
Study 29369177 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual interface
Number of subjects: 65
Study 29369177 — intervention group
Group type: COMPARATOR
Intervention: Real interface
Number of subjects: 65
Study 26597577 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice pack therapy for 24 hours after surgery
Number of subjects: 30
Study 26597577 — intervention group
Group type: COMPARATOR
Intervention: No cold therapy
Number of subjects: 30
Study 25230144 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg
Number of subjects: 0
Study 25230144 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22775354 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin-ER 600 mg evening (pm)
Number of subjects: 124
Study 22775354 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin-ER 600 mg morning (am)/600 mg pm
Number of subjects: 124
Study 22775354 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin-ER 1200 mg pm
Number of subjects: 124
Study 22775354 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin-ER 600 mg am/1200 mg pm
Number of subjects: 124
Study 22775354 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin-ER 600 mg am/1800 mg pm
Number of subjects: 124
Study 22775354 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin-ER 1200 mg am/1800 mg pm
Number of subjects: 124
Study 22775354 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin-ER (all doses)
Number of subjects: 124
Study 20159130 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual Reality task (internet-based assessment of purchasing airline tickets)
Number of subjects: 39
Study 20159130 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report measures (quality of life and functional status questionnaires)
Number of subjects: 39
Study 16352299 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiropramide (100 mg dose)
Number of subjects: 18
Study 16352299 — intervention group
Group type: COMPARATOR
Intervention: Control formulation of Tiropramide (100 mg dose)
Number of subjects: 18
Study 15257956 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rHuEPO) treatment
Number of subjects: 0
Study 15257956 — intervention group
Group type: COMPARATOR
Intervention: OFF-models
Number of subjects: 0
Study 11565838 — intervention group
Group type: EXPERIMENTAL
Intervention: Cloned melanoma antigen-specific T lymphocytes
Number of subjects: 23
Study 11565838 — intervention group
Group type: COMPARATOR
Intervention: IL-2 (125,000 IU/kg subcutaneously daily for 12 days)
Number of subjects: 23
Study 11565838 — intervention group
Group type: COMPARATOR
Intervention: IL-2 (720,000 IU/kg intravenously every 8 h for 4 days)
Number of subjects: 23
Study 10169297 — intervention group
Group type: EXPERIMENTAL
Intervention: Video group (n = 270)
Number of subjects: 255
Study 10169297 — intervention group
Group type: EXPERIMENTAL
Intervention: Video + self-help group (n = 232)
Number of subjects: 255
Study 10169297 — intervention group
Group type: COMPARATOR
Intervention: Routine care (n = 255)
Number of subjects: 255
Study 8099731 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cell Transplantation (ASCT)
Number of subjects: 77
Study 8099731 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (CT)
Number of subjects: 77
Study 3578566 — intervention group
Group type: EXPERIMENTAL
Intervention: Trihexyphenidyl
Number of subjects: 0
Study 3578566 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 0
Study 28414254 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure Ulcer Prevention Program (lifestyle-based treatment administered by healthcare professionals, largely via in-home visits and phone contacts)
Number of subjects: 166
Study 28414254 — intervention group
Group type: COMPARATOR
Intervention: Randomized control group (standard care)
Number of subjects: 166
Study 28414254 — intervention group
Group type: COMPARATOR
Intervention: Nonrandomized control group (standard care)
Number of subjects: 166
Study 28886221 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved version of the tool mark comparison algorithm
Number of subjects: 0
Study 28886221 — intervention group
Group type: COMPARATOR
Intervention: Original tool mark comparison algorithm
Number of subjects: 0
Study 27258530 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Beck Depression Inventory (BDI)-II administered to adults randomly selected from the community (n=221)
Number of subjects: 298
Study 27258530 — intervention group
Group type: COMPARATOR
Intervention: Caregivers of adolescents affected by HIV (n=77)
Number of subjects: 298
Study 23955468 — intervention group
Group type: EXPERIMENTAL
Intervention: FraTrix intervention applied over 9 months during three facilitated team sessions.
Number of subjects: 60
Study 23955468 — intervention group
Group type: EXPERIMENTAL
Intervention: FraTrix intervention practices reporting of patient safety incidents.
Number of subjects: 60
Study 23955468 — intervention group
Group type: COMPARATOR
Intervention: Control group practices (not specified in detail).
Number of subjects: 60
Study 22627027 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent clinical expert committee review of medical files
Number of subjects: 50
Study 22627027 — intervention group
Group type: COMPARATOR
Intervention: Death certificates
Number of subjects: 50
Study 20447532 — intervention group
Group type: EXPERIMENTAL
Intervention: Copeptin and troponin T (TnT) combined measurement on admission
Number of subjects: 1386
Study 18926212 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine bedside placement of a preformed Silastic spring‐loaded silo
Number of subjects: 54
Study 18926212 — intervention group
Group type: COMPARATOR
Intervention: Primary closure
Number of subjects: 54
Study 17806018 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservation of the azygos vein (group A)
Number of subjects: 50
Study 17806018 — intervention group
Group type: COMPARATOR
Intervention: Classical approach with ligation of the azygos vein (group B)
Number of subjects: 50
Study 17806018 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 50
Study 12841925 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% azelastine eye drops, twice daily for 6 weeks
Number of subjects: 139
Study 12841925 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label levocabastine, twice daily for 6 weeks
Number of subjects: 139
Study 12841925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study 10989958 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin-1 (ET-1) infusion at 20 ng/min x kg
Number of subjects: 7
Study 10989958 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin-3 (ET-3) infusion
Number of subjects: 7
Study 10989958 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 7
Study 9149659 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-fatty acids (top quintile intake, median = 6.2 g/day)
Number of subjects: 21930
Study 9149659 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids from fish (highest quintile intake)
Number of subjects: 21930
Study 9149659 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated or cis‐monounsaturated fatty acids, linoleic or linolenic acid, or dietary cholesterol
Number of subjects: 21930
Study 9149659 — intervention group
Group type: EXPERIMENTAL
Intervention: All major coronary events
Number of subjects: 21930
Study 8114055 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual basis administered by physician‐nurse teams (PN)
Number of subjects: 52
Study 8114055 — intervention group
Group type: COMPARATOR
Intervention: Group basis from a team of paramedical professionals (PP)
Number of subjects: 52
Study 3534198 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycine-based oral rehydration solution (glycine-ORS)
Number of subjects: 143
Study 3534198 — intervention group
Group type: COMPARATOR
Intervention: Standard oral rehydration solution (ORS)
Number of subjects: 143
Study 31432380 — intervention group
Group type: EXPERIMENTAL
Intervention: Video Interaction Project (VIP) intervention delivered in tandem with pediatric well-child visits.
Number of subjects: 403
Study 29675616 — intervention group
Group type: EXPERIMENTAL
Intervention: ado-trastuzumab emtansine (T-DM1)
Number of subjects: 0
Study 29675616 — intervention group
Group type: EXPERIMENTAL
Intervention: capecitabine-plus-lapatinib
Number of subjects: 0
Study 29675616 — intervention group
Group type: COMPARATOR
Intervention: T-DM1
Number of subjects: 0
Study 26892210 — intervention group
Group type: EXPERIMENTAL
Intervention: ART restorations plus petroleum jelly (PJ)
Number of subjects: 389
Study 26892210 — intervention group
Group type: EXPERIMENTAL
Intervention: bilayer‐ART restorations plus petroleum jelly (PJ)
Number of subjects: 389
Study 26892210 — intervention group
Group type: EXPERIMENTAL
Intervention: ART restorations plus nanofilled coating for GIC (NC)
Number of subjects: 389
Study 26892210 — intervention group
Group type: EXPERIMENTAL
Intervention: bilayer‐ART restorations plus nanofilled coating (NC)
Number of subjects: 389
Study 24531083 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID-GGA group (75 mg/day diclofenac sodium and 150 mg/day GGA)
Number of subjects: 30
Study 24531083 — intervention group
Group type: COMPARATOR
Intervention: NSAID-FAM group (75 mg/day diclofenac sodium and 20 mg/day famotidine)
Number of subjects: 30
Study 24531083 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID-GGA group
Number of subjects: 30
Study 24327533 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral coronoid hyperplasia treatment group
Number of subjects: 26
Study 24327533 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study 20571299 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives (COCs)
Number of subjects: 0
Study 20571299 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogens in COCs
Number of subjects: 0
Study 20571299 — intervention group
Group type: EXPERIMENTAL
Intervention: Progestagens in COCs
Number of subjects: 0
Study 19022973 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc (10-mg tablets daily until discharge)
Number of subjects: 550
Study 19022973 — intervention group
Group type: COMPARATOR
Intervention: Placebo (daily until discharge)
Number of subjects: 550
Study 16649407 — intervention group
Group type: EXPERIMENTAL
Intervention: S-adenosyl-L-methione (SAMe) 500mg twice daily in slow running infusion for twelve days, ongoing oral 500 mg twice daily until delivery
Number of subjects: 78
Study 16649407 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 3 x 250 mg daily
Number of subjects: 78
Study 16649407 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with both drugs (SAMe and UDCA)
Number of subjects: 78
Study 16649407 — intervention group
Group type: COMPARATOR
Intervention: Control group (SAMe monotherapy)
Number of subjects: 78
Study 12794404 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% hypertonic saline solution (2400 mOsm/kg/H(2)O)
Number of subjects: 20
Study 12794404 — intervention group
Group type: COMPARATOR
Intervention: 20% mannitol (1160 mOsm/kg/H(2)O)
Number of subjects: 20
Study 11082356 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary autograft
Number of subjects: 74
Study 11082356 — intervention group
Group type: COMPARATOR
Intervention: Aortic homograft
Number of subjects: 74
Study 11082356 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-month-old autograft
Number of subjects: 74
Study 9001061 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified hygiene protocol
Number of subjects: 30
Study 9001061 — intervention group
Group type: COMPARATOR
Intervention: Standard hygiene protocol
Number of subjects: 30
Study 1386065 — intervention group
Group type: COMPARATOR
Intervention: Formula A (corn oil-based, low in omega-3)
Number of subjects: 81
Study 1386065 — intervention group
Group type: COMPARATOR
Intervention: Formula B (soy oil-based, ample alpha-linolenic acid)
Number of subjects: 81
Study 1386065 — intervention group
Group type: COMPARATOR
Intervention: Formula C (supplemented with alpha-linolenic acid and marine oils)
Number of subjects: 81
Study 1386065 — intervention group
Group type: COMPARATOR
Intervention: Human milk (naturally containing omega-3)
Number of subjects: 81
Study 1386065 — intervention group
Group type: COMPARATOR
Intervention: Intrauterine nutrition
Number of subjects: 81
Study 6588485 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (1500 mg)
Number of subjects: 16
Study 6588485 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole (1600 mg)
Number of subjects: 16
Study 6588485 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxy-metronidazole
Number of subjects: 16
Study 6588485 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxy-tinidazole
Number of subjects: 16
Study 30580680 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive BP treatment (systolic BP target, <120 mm Hg)
Number of subjects: 1397
Study 30580680 — intervention group
Group type: COMPARATOR
Intervention: Standard BP treatment (systolic BP target, <140 mm Hg)
Number of subjects: 1397
Study 30580680 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive BP treatment
Number of subjects: 1397
Study 30580680 — intervention group
Group type: COMPARATOR
Intervention: Standard BP treatment
Number of subjects: 1397
Study 28423235 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐asparaginase biweekly
Number of subjects: 130
Study 28423235 — intervention group
Group type: COMPARATOR
Intervention: Six‐week PEG‐asparaginase intervals
Number of subjects: 130
Study 25708187 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (15 Hz, 30 min once a day for 5 days at 80% resting motor threshold)
Number of subjects: 11
Study 25708187 — intervention group
Group type: COMPARATOR
Intervention: Placebo rTMS
Number of subjects: 11
Study 25708187 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 11
Study 23888450 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN) ointment
Number of subjects: 240
Study 23888450 — intervention group
Group type: COMPARATOR
Intervention: Vaseline ointment (control)
Number of subjects: 240
Study 21444807 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose CNTF implant
Number of subjects: 0
Study 21444807 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CNTF implant
Number of subjects: 0
Study 21444807 — intervention group
Group type: COMPARATOR
Intervention: Sham surgery
Number of subjects: 0
Study 21444807 — intervention group
Group type: COMPARATOR
Intervention: Combined low-dose/sham group
Number of subjects: 0
Study 19802659 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux sodium (FPX) 2.5 mg/day for 14 days
Number of subjects: 76
Study 19802659 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-FPX)
Number of subjects: 76
Study 16319910 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 20
Study 15589001 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate control therapy
Number of subjects: 89
Study 15589001 — intervention group
Group type: COMPARATOR
Intervention: Rhythm control therapy
Number of subjects: 89
Study 15589001 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality-of-life scores
Number of subjects: 89
Study 11745975 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% recording window with stimulation current in the lower quarter
Number of subjects: 10
Study 11745975 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% recording window with stimulation current in the lower quarter
Number of subjects: 10
Study 11745975 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% recording window with stimulation current in the middle half
Number of subjects: 10
Study 11745975 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% recording window with stimulation current in the middle half
Number of subjects: 10
Study 9014956 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with spinal cord injury (SCI)
Number of subjects: 70
Study 9014956 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with SCI and pressure ulcers
Number of subjects: 70
Study 9014956 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 70
Study 7506470 — intervention group
Group type: EXPERIMENTAL
Intervention: octreotide (200 micrograms/24 h)
Number of subjects: 10
Study 7506470 — intervention group
Group type: COMPARATOR
Intervention: placebo (saline)
Number of subjects: 10
Study 3553496 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril alone
Number of subjects: 626
Study 3553496 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa alone
Number of subjects: 626
Study 3553496 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol alone
Number of subjects: 626